




INVESTOR DAY

Captor Therapeutics
the most innovative company on the WSE*



Legal notice

This document and the information contained herein (unless otherwise indicated) have been prepared by Captor Therapeutics S.A. (the "Issuer") solely for informational purposes. For this notice, the presentation that follows shall mean and include the slides that follow, the oral presentation of the slides by the Issuer or any person on behalf of the Issuer, any question-and-answer session that follows the oral presentation, hard copies of this document, and any materials distributed at, or in connection with the presentation (collectively, the "Presentation"). By attending the meeting at which the Presentation is made, or by reading the Presentation, you will be deemed to have (i) agreed to all of the following restrictions and made the following undertakings and (ii) acknowledged that you understand the legal and regulatory sanctions attached to the misuse, disclosure or improper circulation of the Presentation.

The information contained in this Presentation may not be reproduced or redistributed in any way, in whole or in part, to any other person without the prior written consent of the Issuer. This Presentation does not purport to contain all the information that may be required by the recipient to assess the Issuer or its securities. The Issuer prepared this Presentation based on the information which it has and from sources believed to be reliable. To the extent available, the industry, market, and competitive position data contained in this Presentation come from official or third-party sources. There is no guarantee of the accuracy or completeness of such data.

This Presentation contains neither a complete nor a comprehensive financial or commercial analysis of the Issuer, nor does it present its position or prospects in a complete or comprehensive manner. The Issuer has prepared the Presentation with due care, however certain inconsistencies or omissions might have appeared in it. Therefore it is recommended that any person who intends to undertake any investment decision regarding any security issued by the Issuer shall only rely on information released as an official communication (i.e. current/periodic reports) in accordance with the legal and regulatory provisions.

This Presentation may contain certain forward-looking statements, forecasts, estimates, projections, and opinions ("Forward-looking Statements"). By their nature, Forward-looking Statements involve known and unknown risks, uncertainties, assumptions, and other factors because they relate to events and depend on circumstances that will occur in the future whether or not outside the control of the Issuer. No representation is made or will be made that any Forward-looking Statements will be achieved or will prove to be correct. Actual future results and operations could vary materially from the Forward-looking Statements. Similarly, no representation is given that the assumptions disclosed in this Presentation upon which Forward-looking Statements may be based are reasonable. The recipient acknowledges that circumstances may change and the contents of this Presentation may become outdated as a result. The assumptions included herein do not constitute profit forecasts or profit estimates.

No warranties or representations can be made as to the comprehensiveness or reliability of the information contained in this Presentation. Neither the Issuer nor its directors, managers, advisers or representatives of such persons shall bear any liability that might arise in connection with any use of this Presentation. Furthermore, no information contained herein constitutes an obligation or representation of the Issuer, its managers or directors, its shareholders, subsidiary undertakings, advisers or representatives of such persons.

Data contained in this Presentation is valid as of the day of its preparation. Consequently, this Presentation will not be subject to changes, updates or modifications to account for events which might occur after this day.

This Presentation does not constitute or form part of, and should not be construed as, an offer to sell or issue, or the solicitation of an offer to purchase, subscribe to, or acquire the Issuer or the Issuer's securities, or an inducement to enter into investment activity in any jurisdiction in which such offer, solicitation, inducement or sale would be unlawful before registration, exemption from registration or qualification under the securities laws of such jurisdiction. No part of this Presentation, nor the fact of its distribution, should form the basis of, or be relied on in connection with, any contract or commitment or investment decision whatsoever. This presentation is not for publication, release, or distribution in any jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction nor should it be taken or transmitted into such jurisdiction.

Captor Therapeutics – key developments

Serial announcements of in-vivo data

- ✓ **CT-01:** GSPT1, SALL4 + undisclosed target
 - Molecular Glue with unique degradation profile
 - Strong efficacy in Hepatic Cancer animal models after oral dosing
- ✓ **CT-03:** MCL-1
 - First-in-class MCL-1 degrader
 - Animal studies: show potent and sustained MCL-1 degradation after single dose; tumour regression shown in leukaemia animal models

CT-02 target remains undisclosed, but potent candidate molecules are now advancing

Optigade™ platform

Captor's unique capacities in Biophysics, Structural Biology and Chemistry are bearing fruit

✓ LiLis - new ligase ligands

- Potent ligands obtained against 2 novel ligases show the way to next generation degraders

Collaborations

- Partnership with Sosei Heptares is moving forward well
- Discussions advance with potential new partners



**LISTED ON THE WARSAW
STOCK EXCHANGE FROM
APRIL 2021**

OUR MISSION

Inspired by nature, we are reprogramming protein fate to treat the untreatable...

- Available funding secured - PLN 214 M – PLN 118 M cash, PLN 96 M agreements with NCBR (as of 31/12/2021)
- CT was awarded the title of Stock Exchange Company of the Year in the Innovation category by Puls Biznesu


GLOBAL LANDSCAPE – TPD TECHNOLOGY

Targeted Protein Degradation – a revolution

Targeted Protein Degradation (TPD) opens a new chapter in Pharmaceuticals

- TPD drugs have the potential to address unmet medical needs with a unique mode of action inaccessible to classic approaches
- A record value of signed partnering agreements in 2020 (cumulative potential of \$198.2 billion)
- The 2021 macroeconomic situation, saw a decrease in values, yet it was the second highest year for equity raised in the last decade
- Despite a difficult 2021, biotechnology is and will be the industry of the future as many diseases are without adequate treatments

Value of equity raised in Biotech



Source: BioWorld

Biopharmaceutical market to reach \$ 525 billion by 2025*



- TPD, like other biopharmaceutical sectors, benefits from the scientific developments in biology
- But TPD has a unique position compared to other breakthrough modalities: it uses small molecule drugs
- First generation molecular glues are already on the market and sell billions of dollars
- Intense R&D spending and growing know-how is advancing development of the next generation
- TPD is also unique as every public TPD company has had its IPO at preclinical stage

Overview of selected TPD specialist companies in terms of their drug candidate's development stage



CAPTOR'S POSITIONING

Vision – become a world-leading drug discovery company based on Targeted Protein Degradation



- Based in Wrocław (Poland) and Basel (Switzerland)
- Significantly oversubscribed IPO in April 2021
- Strong support of non-dilutive funding from NCBR
- Five drug programs in large potential markets
- ~98 employees on board, almost half of them are PhD level specialists
- 1,100 m² of laboratory space equipped with state-of-the-art equipment

A global, highly qualified team:



An experienced leadership team



Tom Shepherd, Ph.D.
Chief Executive Officer

- Chief Executive Officer
- 30 years experience in Business Development and CEO
- Led 12 licensing transactions resulting in > \$3 B in sales
- 6 private investment rounds and 3 IPOs.



Michal Walczak, Ph.D.
Chief Scientific Officer

- Ph.D. ETH Zurich,
- Post-doc FMI Basel (Novartis Research Foundation) researching TPD
- 10 years experience in drug discovery and TPD



Radoslaw Krawczyk
Chief Financial Officer

- Chief Financial Officer
- Finance & banking Warsaw School of Economics
- MBA Marseille Graduate School of Management
- 20 years in Financial Strategy
- 8 years in WSE listed companies
- 2 IPOs



Sylvain Cottens, Ph.D.
Co – founder – SVP Chemistry

- Ph.D. EPFL Lausanne,
- Post-doc Caltech, USA
- Scientific expert & leader with 25+ years experience in Novartis
- Co-inventor of Afinitor and co-developer of Gilenya (both blockbuster drugs)

EDUCATION



ETH




EPFL

PREVIOUS EXPERIENCE



Company pipeline projects



*Preclinical stage include IND-enabling studies
 **First in Human; at least 2 projects expected to enter Phase 1 by 2023
BID – Bi-functional Degradar; **MG** – Molecular Glue

Captor's Optigrade™ platform

Molecular Glues

Small molecules with good drug properties that stabilize the interaction between the E3 Ligase and the target

- Rational screening paradigm for new targets
- Library of proprietary CRBN-based molecular glues
- Selective degradation and novel efficacy profiles

Evolving LiLis™ Platform

To develop new generation degraders exploiting novel E3 ligases

- Library of E3 Ligase proteins and ligands
- Potential improved safety
- Reduced opportunity for resistance
- Tissue specific expression

Molecular
Glues



New
E3 Ligases

Bifunctional
Degraders

Platform differentiation

- Lead compounds both in molecular glues and bifunctional degraders
- Structure-based hit finding and lead optimization
- Novel and proprietary chemistry


Bifunctional Degraders

A modular approach to degrader discovery

- Many CRBN-based degraders co-degrade Ikaros and Aiolos with side effect consequences
- Captor's CRBN ligands have improved selectivity profile
- Includes degraders against previously undrugged targets




Principle of Targeted Protein Degradation





Rationalization of Molecular Glue Discovery



ZnF Target	Non-ZnF Target
ZNF517	PLK kinases
ZNF582	NIMA kinases
ZNF653	PAK kinases
IKZF1/3	GTPases
ZFP91	WD repeat
IKZF2/4	Chaperones
PATZ1	Phosphatases

Sievers Q., Petzold G. et al. *Science* (2018) 362(6414)

2 drug candidates advancing towards the clinics

Molecular Glues

Project:

CT-01

Positioning:

Unique degradation profile

Main indication:

hepatocellular carcinoma

- Anticancer activity in different HCC models *in vitro*
- Excellent *in vivo* efficacy with oral administration
- Full tumour regression observed with doses of 10 and 25mg/kg

Bifunctional Degraders

Project:

CT-03

Positioning:

First-in-class MCL-1 degrader

Main indications:

blood cancers

- Anticancer activity *in vitro* in both liquid and solid tumors
- Potent and sustained MCL-1 degradation *in vivo* after single injection
- Cancer cell killing and tumour shrinkage *in vivo*

TO ENTER CLINICAL PHASE IN 2023



Broad Applicability of the CT-02 Molecular Glues

Molecular Glues

Project: CT-02


Main indication: Autoimmunity, Oncology, CNS

- According to forecasts by the World Health Organization, the number of new leukemia cases worldwide will increase from about 437,000 in 2018 to about 603,000 in 2035, and the number of deaths from leukemia will increase from about 310,000 to about 444,000



New
Ligases

Underexplored Opportunities in Novel Ligases




Families E3 ubiquitin ligases


- There are ~600 different E3 ubiquitin ligases
- So far, ligands identified to only a few E3 ligases
- All clinical-stage degraders based on CRBN (and one on VHL)

New
Ligases

Novel E3 Ligase with Unique Expression Profile



Novel E3 Ligase



Novel E3 Ligase Offers Application in Cancer without affecting healthy cells

Summary of scientific discovery

- Highly advanced pre-clinical pipeline with spectacular results
- Rationalization of molecular glue discovery engine
- Identification of novel E3 ligases with greatly attractive properties




FINANCIAL RESULTS

Full year on the Stock Exchange

Financing from the IPO in April 2021, allowed us to accelerate business and corporate processes
We would like to thank our shareholders for their trust and support

Proceeds from the IPO opened a new phase of the Company's development and will allow it to:

- ✓ finance the current research and development projects and diversify sources of financing in order to ensure the possibility of carrying out research
- ✓ finance the expansion and acquisition of technical and scientific infrastructure necessary to carry out R&D projects
- ✓ finance marketing activity and legal protection, including patent protection
- ✓ employ qualified staff for the Company;
- ✓ finance the opening and operation of a laboratory in Basel (Switzerland)



Market capitalization (April, 2022)

PLN 685 M

IPO value (April 2021)

~PLN 150 M

Reduction of the retail tranche in IPO

~92%

Captor named by Puls Biznesu (main Polish business daily) as a company with the most innovative products and services on GPW.



Selected consolidated financial data

Revenues and financial results (PLN thousands)

	FY 2021	FY 2020
Research and development income	3 986	-
Cost of services sold	741	-
Net loss	-32 572	- 12 694

Cash flows (PLN thousands)



	FY 2021	FY 2020
Net cash operating activities	-28 473	-595
Net cash investing activities	-5 113	-212
Net cash financing activities	140 875	-881

Group indicators (%)

	FY 2021	FY 2020
Total debt ratio ¹	13.47%	103.89%
Long-term debt ratio ²	15.37%	25.30%
short-term debt ratio ³	84.63%	74.70%

¹ total liabilities/total assets; ² long-term liabilities/total liabilities; ³ short-term liabilities/total liabilities

Consolidated statement of financial position (PLN, M)



Available funding secured (PLN M; as of 31/12/2021):

- **118 M PLN** cash
- **96 M PLN** agreements with NCBR

Strong balance sheet and investments as foundation for further development

1.

HIGHLY QUALIFIED PERSONNEL (Data as of 31/12/2021)

Number of employees	98
Number of research workers	87
Percentage of scientists with PhD	49%

22% increase in research
workers in 2021

2.

INCREASED FIXED ASSETS BASE

- ~ PLN 4 M Spectrometr
- ~ PLN 1 M Cell sorter

3.

FINANCIAL RESOURCES (Cash and cash equivalents)

PLN 214 M as of 31/12/2021,
PLN 96 M NCBR grants + PLN 118 M cash

PLN 214 M from IPO
and NCBR grants

PLANS FOR THE FUTURE

Executive summary

- Major *in-vivo* project milestones in CT-01, CT-03 - molecular targets announced, drug candidates
- CT-02 makes breakthrough with potent degraders against an autoimmune target
- Project milestones CT-01, CT-03 - molecular targets announced, drug candidates
- Effective collaboration with Sosei Heptares, discussions ongoing with other companies
- Successful IPO
- Strong financial resources to realise our IPO objectives
- Continuing to build a strong international team
- Puls Biznesu Award - the most innovative company on the Warsaw Stock Exchange
- State of the art laboratory and continuous investment in new capabilities, such as proteomics
- Increasing international awareness of Captor in the pharma industry and with international investors due to our strong newsflow and business development
- BioInmed - co-founders

Near term objectives and milestones

WORKING TO DEVELOP DRUG CANDIDATES

- ▶ Announce additional *in-vivo* results in our pipeline projects
- ▶ Initiation of IND-enabling studies for the most advanced programs as they move towards the clinic
- ▶ Strengthening of our presence in Switzerland, positioning the Company for international growth

PARTNERSHIPS WITH OTHER ENTITIES

- ▶ Continuing the Sosei Heptares collaboration
- ▶ Execution of value creating contracts with further partners

PLATFORM DEVELOPMENT

- ▶ Advancing our new ligase ligands to develop POC for degraders beyond CRBN

Q&A SESSION



**Captor
Therapeutics®**



Captor Therapeutics S.A

ul. Duńska 11
54-427 Wrocław, Polska



Captor Therapeutics GmbH

Gewerbestrasse 24
4123 Allschwil, Schweiz

IR Contact:

Marta Świąćicka

m.swiecicka@captortherapeutics.com

Media and IR Contact:

captortherapeutics@pov.pl

